Valuation : Axsome Therapeutics, Inc.

Market Cap 1.09TCr 936.29Cr 880.69Cr 803.86Cr 1.5TCr 1,03200Cr 1.51TCr 10TCr 4.03TCr 53TCr 4.09TCr 4TCr 1,67100Cr P/E 2026 *
-77.7x
P/E 2027 * 45.1x
Enterprise Value 1.07TCr 922.83Cr 868.03Cr 792.3Cr 1.48TCr 1,01700Cr 1.49TCr 10TCr 3.98TCr 52TCr 4.03TCr 3.94TCr 1,64700Cr EV / Sales 2026 *
11.1x
EV / Sales 2027 * 6.69x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 week+3.85%
Current month+3.85%
1 month-3.18%
3 months-11.89%
6 months+27.48%
Current year+38.28%
1 week 165.8
Extreme 165.8
184
1 month 165.8
Extreme 165.8
196.75
3 years 52.74
Extreme 52.74
225.3
5 years 19.48
Extreme 19.485
225.3
Manager TitleAgeSince
Chief Executive Officer 57 12/01/2012
Director of Finance/CFO 51 16/05/2018
Chief Operating Officer 42 01/04/2014
Director TitleAgeSince
Chairman 57 12/01/2012
Director/Board Member 64 01/12/2014
Director/Board Member 58 01/12/2014
Change 5-day change 1-year change 3-year change Capi.($)
+0.51%+3.85%+67.12%+132.85% 1.08TCr
-2.10%+1.41%+41.32%-1.81% 8.27TCr
+0.94%+1.88%-16.46%-34.82% 5.99TCr
-3.59%-0.01%+458.19%+29.52% 5.81TCr
-1.77%-5.14%-9.07%+29.36% 5.03TCr
-1.62%-3.90%0.00%+149.76% 4.66TCr
-3.77%-1.92%+51.06%-18.69% 3.26TCr
-1.85%+0.96%+43.58%+96.06% 2.57TCr
-1.09%-3.47%-2.81%+183.45% 2.25TCr
+1.56%+1.60%+65.46%+107.92% 1.63TCr
Average -1.01%+0.54%+69.84%+67.36% 4.39TCr
Weighted average by Cap. -1.06%+1.12%+81.65%+42.23%

Financials

2026 *2027 *
Net sales 97Cr 83Cr 78Cr 71Cr 133.12Cr 9.16TCr 133.86Cr 926.13Cr 358.14Cr 4.68TCr 362.82Cr 354.86Cr 15TCr 156.21Cr 134.36Cr 126.38Cr 115.35Cr 215.21Cr 15TCr 216.42Cr 1.5TCr 579.01Cr 7.57TCr 586.57Cr 573.7Cr 24TCr
Net income -14Cr -12Cr -11Cr -10Cr -19Cr -1.33TCr -19Cr -134.51Cr -52Cr -680.09Cr -53Cr -52Cr -2.15TCr 26Cr 22Cr 21Cr 19Cr 35Cr 2.42TCr 35Cr 244.73Cr 95Cr 1.24TCr 96Cr 94Cr 3.92TCr
Net Debt -16Cr -13Cr -13Cr -12Cr -22Cr -1.48TCr -22Cr -149.98Cr -58Cr -758.32Cr -59Cr -57Cr -2.4TCr -44Cr -37Cr -35Cr -32Cr -60Cr -4.13TCr -60Cr -417.27Cr -161.36Cr -2.11TCr -163.47Cr -159.88Cr -6.68TCr
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
-
Date Price Change
08/26/08 €178.80 +0.51%
07/26/07 €177.90 0.00%
04/26/04 €177.90 -0.95%
03/26/03 €179.60 -1.05%
02/26/02 €181.50 +3.42%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
207.82USD
Average target price
285.42USD
Spread / Average Target
+37.34%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!